Animal model for allergic disorders
View Patent ↗An animal suitable as a model for an allergic disorder, wherein the animal is an immuno-modulated animal which has been sensitized with an antigen under a specific pathogen free environment such that when the animal displays allergy symptoms caused by the antigen.
1. An NC/Nga mouse that has been sensitized with a mite extract by multiple sequential injections of mite antigen over a period 18 days or less in a pathogen-free environment,
wherein said mouse exhibits at least one symptom of severe dermatitis in a shorter period of time than a conventional NC/Nga mouse; or
wherein said mouse develops dermatitis lesions sufficiently severe for evaluating the effectiveness of a medicine by day 18.
2. The NC/Nga mouse of claim 1 , which exhibits at least one symptom of severe dermatitis in a shorter period of time than conventional NC/Nga mice.
3. The NC/Nga mouse of claim 2 , wherein said symptom is a skin lesion on the ear(s) of the mouse.
4. The NC/Nga mouse of claim 1 , which develops dermatitis lesions sufficiently severe for evaluating the effectiveness of a medicine by day 18.
5. The NC/Nga mouse of claim 1 , which develops skin lesions characterized by erythema, edema, excoriation, and/or scaling.
6. The NC/Nga mouse of claim 1 , which develops skin lesions characterized by erythema.
7. The NC/Nga mouse of claim 1 , which develops skin lesions characterized by ear swelling.
8. A method of producing the NC/Nga mouse of claim 1 , comprising:
maintaining a NC/Nga mouse in a specific pathogen free environment and sensitizing the ear(s) of the mouse with the mite extract.
9. A method of producing the NC/Nga mouse of claim 1 , comprising:
maintaining a NC/Nga mouse in a specific pathogen free environment and sensitizing the ear(s) of the mouse with the mite extract by multiple sequential injections of mite antigen over a period of 18 days or less in a pathogen-free environment.
10. A method of screening for an agent for effectiveness against atopic dermatitis, comprising:
applying at least one agent to the mouse of claim 1 ,
determining whether the agent reduces one or more symptoms of atopic dermatitis,
correlating a reduction in said one or more symptoms with effectiveness of said agent against atopic dermatitis, or
correlating a lack of reduction in said one or more symptoms with ineffectiveness of said agent against atopic dermatitis.
11. The method of claim 10 , wherein said determining comprises measuring the affected areas of the mouse.
12. The method of claim 10 , wherein said determining comprises measuring the affected areas at the ventral sides of the ears of the mouse.
13. The method of claim 10 , wherein said determining comprises measuring anti-Dp-specific IgG levels in said mouse.
14. The method of claim 10 , wherein said determining comprises measuring the concentration of at least one cytokine in said mouse.
15. The method of claim 10 , wherein said determining comprises measuring degranulation of mast cells in said mouse.
16. The method of claim 10 , wherein said determining comprises measuring eosinophil infiltration in said mouse.